Skip to main content
. Author manuscript; available in PMC: 2021 Jun 21.
Published in final edited form as: Schizophr Res. 2019 Feb 6;208:384–389. doi: 10.1016/j.schres.2019.01.016

Table 1.

Demographic and clinical characteristics. Means +/− standard deviations are given where applicable. TAU = treatment as usual group. TCT = targeted cognitive training. SAPS = Scale for the Assessment of Positive Symptoms. SANS = Scale for the Assessment of Negative Symptoms.

TAU TCT p

Sample size 22 24 0.75
Age 35.73 (13.00) 34.54 (12.13) 0.55
Gender: Males 9 (41% 13 (54%) 0.61
Hispanic 6 (27%) 4 (17%)
Race
 African American 3 (14%) 5 (21%) 0.51
 Asian 2 (9%) 1 (4%)
 Caucasian 12 (55%) 13 (54%)
 More than one race 5 (23%) 3 (12%)
 Native American 0 (0%) 2 (8%)
Education 11.95 (2.17) 11.71 (1.99) 0.69
Illness duration 15.23 (12.78) 16.12 (13.67) 0.82
Chlorpromazine equivalents 982.534 (758.10) 1329.42 (972.78) 0.82
SAPS 5.36 (5.02) 6.46 (4.26) 0.62
SANS 13.09 (3.41) 12.96 (4.19) 0.22
Days to follow-up 99.30 (24.26) 89.44 (19.79) 0.2
Hours of training 27.97 (10.20)